Apellis Pharmaceuticals (NASDAQ: APLS)
Apellis Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Apellis Pharmaceuticals Company Info
Apellis Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
News & Analysis
Why Shares of Apellis Pharmaceuticals Were Down Wednesday
A short-seller report sent the stock tumbling.
Why These 3 Nasdaq Stocks Buckled Today
The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today.
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today
These three biotech stocks were on the volatile side today.
2 Best Growth Stocks to Buy in April
Takeover interest is spurring these two biotech stocks higher.
Wall Street Upgraded This Stock's Price Target After a New Approval: Is It a Buy?
The company's lead therapy was just approved for another indication.
Why Apellis Pharmaceuticals Stock Surged This Week
A highly eventful five days for the company saw bulls pile into its shares.
Here's Why Apellis Pharmaceuticals Is Getting Hammered Today
Conflicting clinical trial results for the company's lead candidate are to blame.
Is Apellis Pharmaceuticals a Buy?
The pre-commercial company is looking to take on a $23 billion industry leader. Promising late-stage clinical results suggest it may have a shot.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.